Articles tagged with Breast Cancer
A worldwide study of 100,000 women has discovered two new genetic variants associated with an increased risk of breast cancer. The variants are specifically linked to the most common form of breast cancer, oestrogen receptor positive, providing important clues about its causes and potential leads for treatment discovery.
Researchers at UNC Chapel Hill have developed a device that can deliver chemotherapy drugs directly into tumor tissue, allowing for potential life-saving surgeries and increased life expectancy. The device uses electric fields to target poorly vascularized tumors, which are difficult to treat with standard IV chemotherapy drugs.
A new research by Dr Alessandra Ghigo found that inhibiting the activity of phosphoinositide 3-kinase gamma (PI3K?) protected mice with hypertension from developing heart failure. The study also showed that a PI3K? inhibitor could synergise with chemotherapy to delay tumour growth and prevent cardiotoxicity.
Researchers discovered clusters of gene-blocking microRNAs expressed only in oligometastatic cells, which can shut down specific genes involved in metastasis. These findings suggest microRNAs could provide a personalized biomarker to predict tumor aggressiveness and guide effective treatment.
A new study published in Journal of Clinical Oncology finds that ultrasound can help surgeons decide whether to remove only a few or all underarm lymph nodes from breast cancer patients who have received chemotherapy, reducing the risk of complications and saving healthcare costs.
A new study reveals distinct methylation patterns in primary biopsy breast cancer cells, indicating better or worse prognosis. This epigenetic signature can stratify triple-negative breast cancers into two sub-groups, allowing for more precise disease management and potential improved outcomes.
Researchers at Dartmouth's Norris Cotton Cancer Center have identified ERBB4 as a driver protein in breast cancers that have developed resistance to HER2 targeted therapies. The discovery suggests that anti-ERBB4 drugs could be highly beneficial for patients who no longer respond to first or second-line treatments.
Researchers at NYU Langone Health have discovered a new pathway to slow down tumor growth in cancers with BRCA1 and BRCA2 genetic mutations. By inhibiting the action of polymerase theta enzyme, cancer cell growth can be cut by more than half.
A UTSW study reveals a strong correlation between low levels of beclin 1 and both triple-negative breast cancer incidence and poor prognosis. Patients with low beclin 1 activity had a 67% increased risk of dying from breast cancer compared to those with higher levels.
Researchers at H. Lee Moffitt Cancer Center & Research Institute found that low levels of tristetraprolin (TTP) protein are associated with more aggressive tumors and poorer prognosis in breast and lung cancer patients. A network of 50 genes linked to TTP is present in various tumor types, suggesting potential therapeutic strategies.
A new study published in The Lancet Oncology found that older women with early-stage hormone-receptor positive breast cancers who receive hormone treatment and surgery can safely omit radiotherapy. This group of patients is at low risk of cancer recurrence, making radiotherapy unnecessary.
UC Davis researchers found that half of primary care physicians are unfamiliar with the law, and many don't feel comfortable discussing breast density with patients. The study suggests that increased physician education is needed to address this gap and improve patient outcomes.
A new study found that frequent consumption of sugary drinks is associated with an earlier onset of menstruation in girls. The researchers followed 5583 girls aged 9-14 years and found that those who drank more than 1.5 servings of sugary drinks per day had their first period 2.7 months earlier.
Defects in extrusion, a process that helps cells die when overcrowded, may be a common hallmark of invasive tumor types. FAK inhibitors rescued cell death rates to normal and eliminated large cell masses.
A new breast cancer risk prediction model developed by the Mayo Clinic has been shown to be more accurate than the current screening standard in predicting breast cancer risk. The model uses histologic features of biopsied breast tissue and individual patient demographic information, classifying breast cancer risk with a concordance st...
According to the study, death rates from lung cancer are predicted to exceed those for breast cancer among European women in 2015. The rate of cancer deaths is expected to decline overall, with notable exceptions such as lung and pancreatic cancer.
A new analysis found that women with breast cancer have poor knowledge about their illness, with minority patients less likely to know accurate information. The study highlights the need for patient education and provider awareness to improve informed treatment decisions and overall cancer care.
Researchers developed a breast cancer risk prediction model specifically for African-American women, using data from 55,000 women. The new model predicts higher risk and is expected to increase the number of African-American women invited to participate in prevention trials.
A University of Michigan study found that fans and consumers separate an athlete's immoral behavior from their athletic performance more easily. This led to a less severe backlash for Tiger Woods' extramarital affairs compared to Lance Armstrong's doping scandal.
Researchers used next-generation sequencing techniques to analyze archived tissue samples of phyllodes tumors, identifying two genes (EGFR and IGF1R) that were amplified in malignant tumors. The study also found the gene MED12 was frequently mutated in all classifications of phyllodes tumors.
Researchers at Scripps Research Institute discover a promising new treatment for aggressive breast and pancreatic cancers, using a synthetic compound called SR1848. The compound targets the LRH-1 protein, which is involved in hormone synthesis and cholesterol metabolism.
A study of nearly 375,000 US women with invasive breast cancer found that racial and ethnic groups had different rates of early-stage diagnosis and survival. Biological factors, such as tumor aggressiveness and metastatic potential, played a significant role in determining stage at diagnosis.
New research review highlights the link between cytokines and breast cancer, exploring topics such as cytokine-mediated blood vessel formation and immune evasion. The study suggests that cytokines may serve as prognostic factors for breast cancer patients.
Researchers suggest that the tumor microenvironment could play a significant role in cancer treatment and delivery of nanoparticle-based drugs. They found varying levels of drug delivery between two triple-negative breast cancer tumors, highlighting the importance of personalized medicine and better profiling of tumors.
Researchers have discovered a novel breast cancer gene called BCL11A that drives the development and progression of triple-negative breast cancer. The study found that BCL11A is active in approximately eight out of ten patients with basal-like breast cancer, and its activity is associated with a more advanced grade of tumour.
Researchers developed a culturally-based program that increased fruit and vegetable intake among Latina breast cancer survivors, leading to improved clinical outcomes and weight loss. The program's success has implications for other cancer survivors and larger populations.
Researchers at Huntsman Cancer Institute have developed a new tool to estimate prostate cancer risk based on family history, which can help clinicians decide whether a PSA test is appropriate. The study found that two-thirds of Utah men have some increased risk of developing prostate cancer due to their family history.
Researchers at Dartmouth Hitchcock's Norris Cotton Cancer Center developed a prognostic test for E2F4 in ER+ breast cancer, significantly predicting patient outcome regardless of treatment status. The test identifies patients who should receive aggressive follow-up treatment.
A phase 2 clinical trial found that a combination of lower-intensity chemotherapy and targeted drug trastuzumab significantly reduced the risk of cancer recurrence in women with small, HER2-positive breast tumors. After three years, 98.7% of participants were alive and free of invasive breast cancer.
Women undergoing left-side breast cancer radiation therapy can reduce heart exposure by holding their breath, resulting in a 90% disease-free survival rate and a median reduction of 62% in radiation dose. The breath-hold technique also shows a lower risk of ischemic heart disease after 8 years.
Researchers found significant reductions in red and processed meat consumption and increased fruit and vegetable intake among patients who received nutrition education. This led to lower BMI and reduced oxidative stress, potentially decreasing the risk of cancer reoccurrence.
A New York University study found that adherence to cancer prevention guidelines was associated with reduced risk of obesity-related cancers. The study highlights the importance of low alcohol consumption and a plant-based diet in reducing cancer risk, particularly for breast, prostate, and colorectal cancers.
A Mayo Clinic study found that women with atypical hyperplasia have an increased risk of developing breast cancer over time. After five years, 7% had developed the disease, and after 10 years, 13%. The study suggests that these women should be considered high-risk and screened more intensively.
A recent study by UT Southwestern Medical Center researchers confirms that whole-genome sequencing can successfully identify cancer-related mutations in patients. The method was used to analyze the genomes of 258 cancer patients, detecting nearly 90% of clinically identified mutations and discovering additional cancer gene mutations.
A new study published in the Journal of Clinical Oncology found that the risk of developing leukemia after radiation therapy or chemotherapy for early-stage breast cancer is twice as high as previously reported. The study analyzed data from 20,063 breast cancer patients and found a cumulative risk of 0.5 percent.
A study by The Wistar Institute found that a polymorphism in the TLR5 gene affects tumor progression and inflammation in breast and ovarian cancers. In individuals with functional TLR5 expression, commensal bacteria stimulate IL-6 production, leading to suppressed antitumor immune activity.
Researchers Stanton McHardy and Rong Li will lead a collaborative team to develop next-generation breast cancer treatment drugs, with the goal of harnessing anti-tumor activity against breast cancers. They aim to analyze new small molecules that regulate the ER-beta pathway, which has shown promise in treating breast cancer.
Researchers have developed a microwave imaging system that can produce 3D images of the breast, including the location of cancerous tissue. The system uses dielectric properties to differentiate between normal and cancerous tissue, offering better specificity than current methods.
Research shows adding chemotherapy drug carboplatin or blood vessel-targeting drug bevacizumab to standard preoperative chemotherapy increases pathologic complete response rates for women with basal-like triple-negative breast cancer. The drugs also showed benefits in certain gene signatures associated with aggressive disease.
The study found that Herceptin significantly improved 10-year survival from 75 percent to 84 percent when added to chemotherapy. Additionally, the 10-year disease-free survival rate increased from 62 percent to 74 percent with the addition of trastuzumab.
Researchers found that too much Rbm38 reduces p53 levels, increasing cancer risk, while too little Rbm38 causes premature aging. The study suggests manipulating Rbm38 could have therapeutic benefits by targeting p53 in tumor cells.
The EORTC10085/TBCRC/BIG/NABCG International Male Breast Cancer Program found significant improvements in survival for men with breast cancer, but not as high as for women. The study revealed distinct biological characteristics of male breast cancer, including lower rates of hormonal therapy and breast-conserving surgery.
A recent study published in JNCI Journal of the National Cancer Institute found no association between migraine and breast cancer. The researchers analyzed data from 115,378 women and concluded that migraine was not associated with breast cancer risk or differences in endogenous sex hormone levels.
Dr. Jane Holland's study identified the main driver of basal breast cancer's aggressiveness and targeted treatments to combat it. Her work aims to test inhibitors in human breast cancer tissue, potentially leading to new and effective treatments.
The study found tamoxifen reduced breast cancer rates by around 30% and oestrogen receptor positive invasive cancer by 35%. After 20 years, the estimated risk of developing breast cancer was 8% in the tamoxifen group, compared to 12% in the placebo group.
Research reveals that blocking androgen receptors can reduce the growth of estrogen-positive breast cancers and kill triple-negative breast cancer cells. Combining these drugs with HER2 or mTOR-targeting therapies shows promise for increased effectiveness in treating breast cancer.
A phase-Ib clinical trial found durable responses in almost one out of five patients with metastatic triple-negative breast cancer treated with pembrolizumab. The treatment produced significant activity, with five patients experiencing complete or partial responses, and seven others showing stable disease.
A new study reveals that two-thirds of women treated for early-stage breast cancer in the US receive longer radiation therapy than necessary, despite multiple randomized trials and professional society guidelines showing that hypofractionated radiation is clinically effective and less costly.
Researchers identified two subtypes of breast cancer, Epi-Basal and Epi-Luminal B, which differ in their epigenetic patterns. The subtype Epi-Luminal B is associated with reduced survival rates and requires adjuvant chemotherapy.
A study published in JAMA found that many breast cancer surgery patients do not receive shorter radiation treatment, despite guidelines recommending it for selected patients. Hypofractionated WBI has been shown to be equally effective as conventional WBI but with lower health care costs and reduced treatment burden.
A phase II trial found that a combination of bortezomib and fulvestrant delayed disease progression in post-menopausal women with hormone-receptor-positive metastatic breast cancer. The study showed a doubled rate of survival at 12 months compared to fulvestrant alone.
A University of Colorado Cancer Center study reveals that triple-negative breast cancer cells process tryptophan to promote survival while detached, allowing them to metastasize. The kynurenine pathway, specifically the enzyme TDO2, plays a key role in degrading tryptophan and evading anoikis.
The German Breast Group study found nab-paclitaxel (ABRAXANE) demonstrates significant benefit for patients with early high-risk breast cancer when compared to conventional solvent-based paclitaxel. Nab-paclitaxel achieved a 9% absolute improvement in pathological complete response rate, outperforming traditional chemotherapy.
Researchers have identified a novel therapeutic approach using gamma secretase inhibitors (GSI) to inhibit Notch and block critical genes involved in tumor growth. The study suggests that GSI may optimize existing endocrine therapies and overcome resistance to cancer drugs.
Researchers found that trastuzumab benefits HER2-positive breast cancer patients do not depend on the number of tumor-infiltrating lymphocytes (S-TILs) in their tumors. The study, which measured S-TILs at diagnosis in over 1,000 patients, showed improved recurrence-free survival when chemotherapy alone was used.
Myriad Genetics announced new studies on its myRisk Hereditary Cancer test, detecting 105% more mutations than conventional BRCA testing. The test also showed promising results in triple negative breast cancer (TNBC) by predicting response to platinum-based therapy. Additionally, the company's BRACAnalysis molecular diagnostic test sig...
Researchers found that women with BRCA1/2 mutations and treated with anthracycline-based chemotherapy have low risk of cardiac dysfunction. Most participants had normal heart function, with only a few showing borderline reductions in heart function.
James Ingle, a renowned breast cancer expert at Mayo Clinic, has been awarded the 2014 William L. McGuire Memorial Lecture Award for his groundbreaking research on pharmacogenomics in breast cancer treatment. His work aims to develop personalized approaches to prevent breast cancer in high-risk women by identifying genetic biomarkers t...
A new study suggests that supplementing breast cancer screening for women with dense breasts may not be the most effective approach. Instead, it could lead to an increase in unnecessary biopsies, highlighting the need for alternative methods to screen these high-risk individuals.
Researchers found that up to 45% of breast tumors exhibit genetic alterations affecting the CYP2D6 gene, leading to distorted patient genotypes. This has significant implications for tamoxifen therapy, which relies on accurate CYP2D6 testing to guide treatment.